The role of cytokines in cancer-related fatigue
- 15 September 2001
- Vol. 92 (S6) , 1684-1688
- https://doi.org/10.1002/1097-0142(20010915)92:6+<1684::aid-cncr1497>3.0.co;2-z
Abstract
Fatigue is prominent in cancer patients and probably multifactorial in origin. Factors contributing to fatigue include anemia, weight loss, fever, pain, medication, and infection. In cancer patients, many of these factors are influenced by a frequently disrupted balance between endogenous cytokine levels and their natural antagonists. Indeed, cancer cells and the immune system appear to overexpress a range of cytokines in patients with malignancies. Some of these cytokines act as autocrine or paracrine growth factors for the neoplastic tissue while simultaneously causing secondary symptoms related to fatigue. For instance, cancer-associated anemia may be due to a blunted erythropoietin response and/or cytokines (interleukin-1 [IL-1], IL-6, tumor necrosis factor-alpha [TNF-alpha]), which suppress erythropoiesis. Cancerous cachexia, a wasting syndrome and a hallmark of cancer, can be attributed to loss of appetite or enhanced energy expenditure. Several different interleukins, as well as TNF, interferon-gamma, and leukemia inhibitory factor, act as cachectins in animal models. Similarly, fever and night sweats are influenced by pyrogenic cytokines. Recently, molecules that function as cytokine antagonists have been identified. These molecules may be exploitable in combating the components of cancer-related fatigue, and may inhibit tumor growth as well.Keywords
This publication has 27 references indexed in Scilit:
- Clinical Correlates of Elevated Serum Levels of Interleukin-6 in Patients with Untreated Hodgkin's DiseaseThe American Journal of Medicine, 1997
- Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma.Journal of Clinical Oncology, 1995
- Cytokines: Interleukins and Their ReceptorsPublished by Springer Nature ,1995
- Altered levels of interleukin-1 beta and interleukin-1 receptor antagonist in chronic myelogenous leukemia: clinical and prognostic correlatesBlood, 1994
- Inhibition of acute myelogenous leukemia blast proliferation by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptorsBlood, 1992
- Suppression of chronic myelogenous leukemia colony growth by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors: a novel application for inhibitors of IL-1 activityBlood, 1991
- Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancerAmerican Journal of Obstetrics and Gynecology, 1991
- A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients.Journal of Clinical Oncology, 1988
- Phase I study of multiple dose intramuscularly administered recombinant gamma interferon.Journal of Clinical Oncology, 1986
- Clinical toxicity of interferons in cancer patients: a review.Journal of Clinical Oncology, 1986